CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced ...

I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision ...

Shares of Larimar Therapeutics (NASDAQ:LRMR) declined 9% on Wednesday after the clinical-stage biotech firm revealed the ...

Oxford Square Capital (NASDAQ:OXSQ) announced on Friday that it has priced an underwritten public offering of $65 million in aggregate principal amount of 7.75% unsecured notes due 2030. The notes ...

Larimar intends to use the net proceeds from the proposed offering to support the development of nomlabofusp and other pipeline candidates, and for working capital and general corporate purposes, ...

GameSquare's ETH-focused yield generation strategy is built on top of Dialectic's proprietary platform Medici, which applies ...

Achieve Life Sciences plans an underwritten public offering to fund cytisinicline's development for nicotine dependence treatment. Quiver AI Summary Achieve Life Sciences, Inc., a late-stage ...

VeriSign shares declined after the company announced an underwritten secondary offering of its common stock by affiliates of Berkshire Hathaway. The stock fell 7.5% to $283.01 in after-hours trading ...

In addition, Femasys has granted the underwriter a 30-day option to purchase up to an additional 540,000 shares of its common stock sold in the public offering.

Xilio Therapeutics, Inc. has announced its intention to launch an underwritten public offering of pre-funded warrants, accompanied by various series of warrants to purchase shares of its common stock.

In addition, Femasys has granted the underwriter a 30-day option to purchase up to an additional 540,000 shares of its common stock sold in the public offering.